Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma

This phase II study will be conducted in two parts (Ⅱa and Ⅱb), with a 21-day treatment cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death, initiation of new anti-tumor treatment or loss of follow-up.

Trial Details

NCT ID
NCT06194656
Phase
PHASE2
Sponsor
Shanghai Institute Of Biological Products
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • HER3 Monoclonal antibodies-Dose A
  • HER3 Monoclonal antibodies-Dose B
  • HER3 Monoclonal antibodies-Dose C
  • HER3 Monoclonal antibodies-Dose D
  • Placebo
  • Cetuximab injection
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • The subjects voluntarily participated in the study and signed the informed consent.
  • Male and female aged between 18 and 75 years old, regardless of gender.
  • Patients with recurrent/metastatic advanced HNSCC who have been diagnosed by histology or cytology, progressed or intolerant after previous immunot…
  • During the screening period, subjects must provide tumor tissues and blood samples for biomarker detection. If the subject does not have an archive…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →